Outcomes from pancreatic ductal adenocarcinoma (PDAC) remain poor and better methods of prognostication and therapeutic approaches are needed. Recent advances in cancer genomics have led to the development of molecular subtypes of PDAC associated with clinical outcomes. Current evidence also suggests that the subtypes have differential response to first-line chemotherapy regimens. PDAC is also characterized by different stroma and immune environments. Further work is needed to confirm the utility of these subtypes to predicting response to different systemic therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377860 | PMC |
| http://dx.doi.org/10.1016/j.suc.2024.04.001 | DOI Listing |
Publication Analysis
Top Keywords
pancreatic ductal
8
ductal adenocarcinoma
8
updates molecular
4
molecular profiling
4
profiling pancreatic
4
adenocarcinoma outcomes
4
outcomes pancreatic
4
adenocarcinoma pdac
4
pdac remain
4
remain poor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!